(Total Views: 583)
Posted On: 08/28/2020 8:52:35 PM
Post# of 9144
erik,
Please read sticky post 181. Posted six years ago today
"we had the “game changer”"
The N-Assay technology and GBS testing
In this scenario involving capturing only 20 % of the US Group B Strep (GBS) market of 5 million tests annually, the total gross revenues are $200 million, production and operating costs $42.5 million and net revenues $157.5 million.
Read More: https://investorshangout.com/post/view?id=192...z6WSoGbmc5
So what happened to this game changer and why hasn't BB brought it to fruition?
I asked mac10, the author of 181, and got no response.
I asked numb1 and got no response.
I asked microcap and he answered me privately. If you want his answer ask him directly. He will probably answer you.
And now I will ask you about one of his failures.
So what happened to this game changer and why hasn't BB brought it to fruition?
Please read sticky post 181. Posted six years ago today
"we had the “game changer”"
The N-Assay technology and GBS testing
In this scenario involving capturing only 20 % of the US Group B Strep (GBS) market of 5 million tests annually, the total gross revenues are $200 million, production and operating costs $42.5 million and net revenues $157.5 million.
Read More: https://investorshangout.com/post/view?id=192...z6WSoGbmc5
So what happened to this game changer and why hasn't BB brought it to fruition?
I asked mac10, the author of 181, and got no response.
I asked numb1 and got no response.
I asked microcap and he answered me privately. If you want his answer ask him directly. He will probably answer you.
And now I will ask you about one of his failures.
So what happened to this game changer and why hasn't BB brought it to fruition?
(5)
(1)
